Here’s the One Thing That Could Make or Break Clover Health Stock

80
3
Favorite

Here’s the One Thing That Could Make or Break Clover Health Stock

InvestorPlace2022-03-04

After Clover Health(NASDAQ:CLOV) reported solid fourth-quarter 2021 results on Feb. 23, investors poured in and drove CLOV stock up 31% before pulling back yesterday.What happened on Thursday to fuel...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（3）

SDG
·2022-03-04
好
Reply
1
Report
KYBoo
·2022-03-04
Goof
Reply
1
Report
Jephthan
·2022-03-04
z
Reply
Like
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1105612374?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-03-04 21:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1105612374","market":"us","top_or_hot":-1,"title":"Here’s the One Thing That Could Make or Break Clover Health Stock","media":"InvestorPlace","content":"<div>\n<p>After Clover Health(NASDAQ:CLOV) reported solid fourth-quarter 2021 results on Feb. 23, investors poured in and drove CLOV stock up 31%  before pulling back yesterday.What happened on Thursday to fuel...</p>\n\n<a href=\"https://investorplace.com/2022/03/the-1-thing-to-make-or-break-clover-health-clov-stock/\">Source Link</a>\n\n</div>\n","source":"lsy1606302653667","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here’s the One Thing That Could Make or Break Clover Health Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere’s the One Thing That Could Make or Break Clover Health Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-04 21:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/03/the-1-thing-to-make-or-break-clover-health-clov-stock/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After Clover Health(NASDAQ:CLOV) reported solid fourth-quarter 2021 results on Feb. 23, investors poured in and drove CLOV stock up 31%  before pulling back yesterday.What happened on Thursday to fuel...</p>\n\n<a href=\"https://investorplace.com/2022/03/the-1-thing-to-make-or-break-clover-health-clov-stock/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CLOV","symbol_name":"Clover Health Corp","start_time":0,"source_url":"https://investorplace.com/2022/03/the-1-thing-to-make-or-break-clover-health-clov-stock/","article_id":"1105612374","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1105612374","pubTimestamp":1646400580,"sourceInfo":{"source_id":"lsy1606302653667","name":"InvestorPlace"},"weMediaInfo":null,"summary":"CLOV stock investors want to know where management's taking its direct contracting business","collect":0,"end_time":0,"defaultTopTitle":"investorplace.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"CLOV":"Clover Health Corp"},"translate_title":"有一件事可以决定三叶草健康股票的成败","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLOV":0.9},"content_text":"After Clover Health(NASDAQ:CLOV) reported solid fourth-quarter 2021 results on Feb. 23, investors poured in and drove CLOV stock up 31%  before pulling back yesterday.What happened on Thursday to fuel an almost 14% — between regular hours and after-hours trading? Read on, and I’ll explain what that one thing could be.The Positives Behind CLOV StockAs I said in the intro, Clover Health’s Q4 2021results on the top line delivered very healthy growth. Revenue in the period increased 160% over last year to $432.0 million, with 2021 revenue up 119% to $1.47 billion. In 2022, it expects total revenue to be $3.2 billion at the midpoint of its guidance, 118% higher than in 2021.President Andrew Toy was excited about the future:“In 2021, physicians responded to nearly one million Clover Assistant suggestions, and the Clover Assistant drove an improvement of more than 1,000 basis points in the MCRs for our Medicare Advantage members whose primary care providers used the Clover Assistant compared to members whose providers didn’t,” he was quoted in the company’s press release.Also contributing to the good cheer was a 124% increase in total lives under Clover Management in 2021 to 129,996. It expects this number to increase by 90% or more in 2022.That led to a normalized Medicare Advantage (MA)-to-Medical Care Ratio (MCR) of 94.5%, 140 basis points lower than 2020. It expects MA-MCR to fall some more in 2022 and 2023.However, the top line isn’t what bothers investors. It’s the fact that Toy and his team can’t make money. Its normalized adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) in 2021 wasminus$213.4 million, 51% worse than in 2020.On the plus side, Clover Health expects to reduce its adjusted operating expenses as a percentage of revenue by 700 basis points to 11% at the midpoint of its guidance from 18% in 2021. That should lower its normalized adjusted EBITDA in 2022.Adding Growth Woes to Profitability WorriesOf the company’s $1.47 billion in revenue in 2021, its direct contracting business accounted for 45%. In 2022, it expects $2.15 billion in revenue from direct contracting, 222% higher than in 2021 and accounting for 67% of overall revenue for the year.Given the company’s not making money, it can’t afford to see any of this revenue disappear. Adding growth woes to profitability woes would be the kiss of death.Source: KoyfinOn Feb. 24, the Centers for Medicare & Medicaid Services (CMS) announced that the Direct Contracting Model would remain, albeit in a redesigned format. The new model is called the Accountable Care Organization (ACO) Realizing Equity Access, and Community Health (REACH).“The Biden-Harris Administration remains committed to promoting value-based care that improves the health care experience of people with Medicare, Medicaid and Marketplace coverage,” said CMS Administrator Chiquita Brooks-LaSure.The ACO REACH will be test-runfrom Jan. 1, 2023 through the end of 2026.I’ve already seen several positive and negative responses from Wall Street. I think it’s too early to tell what this will mean for Clover Health and the rest of the companies operating a direct contracting model. As more information becomes available, investors will have an easier time deciding if the move by CMS is a good one for the company.In the meantime, until Clover Health can demonstrate a pathway to profitability, the prospects of CLOV rising from penny-stock status seem remote.The Bottom Line on CLOV StockWhen I last wrote about Clover Health in December, I suggested that its share price had bottomed.CLOV stock was trading at $4 at the time. We know in hindsight that bottom wasn’t quite in.Although I remain cautiously optimistic about its business, I don’t get a warm fuzzy feeling about the shares. I certainly wouldn’t be buying CLOV stock.However, should the company comment on the changes and what it means for its business going forward, I think the shackles could come off its share price.If you’re an aggressive investor, despite the 31% move over the past week, I’m not sure there’s a ton of downside at this point. The direct contracting model is sticking around. That’s all that matters.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9031939166,"gmtCreate":1646406682135,"gmtModify":1676534126675,"author":{"id":"4095922593671880","authorId":"4095922593671880","name":"SDG","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"4095922593671880","idStr":"4095922593671880"},"htmlText":"好","listText":"好","text":"好","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9031939166","repostId":1105612374,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":9031072340,"gmtCreate":1646403320926,"gmtModify":1676534126005,"author":{"id":"3581501341719005","authorId":"3581501341719005","name":"KYBoo","avatar":"https://static.tigerbbs.com/43072e3bdf1be8a6c0fb9e0d7c8a0558","vip":1,"crmLevel":3,"crmLevelSwitch":0,"authorIdStr":"3581501341719005","idStr":"3581501341719005"},"htmlText":"Goof","listText":"Goof","text":"Goof","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9031072340","repostId":1105612374,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9031045643,"gmtCreate":1646401316351,"gmtModify":1676534125801,"author":{"id":"3574124838722774","authorId":"3574124838722774","name":"Jephthan","avatar":"https://static.tigerbbs.com/2b2057ac00b208220c9641c12bf79c7a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3574124838722774","idStr":"3574124838722774"},"htmlText":"z","listText":"z","text":"z","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9031045643","repostId":1105612374,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":80,"commentSize":3,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}